We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcome and molecular measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia patients with MEF2D fusions.
- Authors
Sun, Kai; Chen, Wen‐Min; Wang, Xu; Zhao, Xiao‐Su; Li, Ling‐Di; Hao, Yue; Wang, Jun; Xu, Nan; Jiang, Qian; Jiang, Hao; Xu, Lan‐Ping; Wang, Yu; Zhang, Xiao‐Hui; Huang, Xiao‐Jun; Qin, Ya‐Zhen
- Abstract
All Studies concerning pediatric B-ALL showed that I MEF2D i fusion was associated with high-risk.[[4], [6], [8]] However, the risk defined by I MEF2D i fusions in adult patients was not consistent. Outcome and molecular measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia patients with MEF2D fusions Seven patients had I MEF2D i :: I BCL9 i , 7 had I MEF2D i :: I HNRNPUL1 i , 1 had I MEF2D i :: I DAZAP1 i and 1 had I MEF2D i :: I FOXJ2 i , respectively, but none of patients had partners I SS18 i , I CSF1R i or I HNRNPH1 i . As a result, adult B-ALL patients with I MEF2D i fusions had quite good responses to induction regimen, with the majority achieving CR after one course and all achieving CR after two courses.
- Subjects
LYMPHOBLASTIC leukemia; ACUTE leukemia
- Publication
Hematological Oncology, 2023, Vol 41, Issue 3, p594
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3114